



January 31, 2023

Contact: Benjamin Butz, Director of Membership and Stakeholder Engagement

Phone: (202) 222-0905

Email: [ben.butz@fdli.org](mailto:ben.butz@fdli.org)

## Food and Drug Law Institute Announces Three New Board Members and Two Officers

Washington, DC – The Food and Drug Law Institute (FDLI) is pleased to announce the addition of three new members to its [Board of Directors](#): Adora Ndu, Bridgebio Pharma; Vernessa Pollard, McDermott Will & Emery LLP; and Zach Rothstein, AdvamedDx. They join 13 other highly respected leaders in the food and drug law field in serving on the FDLI Board.

**Adora Ndu** is the Chief Regulatory and interim Legal Officer at Bridgebio Pharma, where she brings over 15 years of complementary experience in drug development and regulatory affairs. Her expertise incorporates regulatory strategy, patient engagement, prescription drug promotion, and policy for U.S. and international markets.

**Vernessa Pollard** is a Partner, McDermott Will & Emery LLP and is Co-Chair of their Life Sciences practice and leads the FDA practice. A thought-leader on digital health and regulatory issues, Vernessa works alongside life sciences, medical device and technology companies, helping them navigate FDA regulatory complexities to bring novel technologies and cutting-edge products to market. She is a recognized leader, with numerous accolades, in the life sciences community.

**Zach Rothstein**, is the Executive Director of AdvamedDx. In this role, Zach directs the policy, advocacy, communications, regulatory, payment and legislative strategy and operations of the association, which represents manufacturers of in vitro diagnostic (IVD) clinical tests in the U.S. and abroad.

In addition, FDLI announces the following Executive Committee changes: Freddy A. Jimenez, Senior Vice President and General Counsel, Celldex Therapeutics has been named Chair and Daniel Kracov, Partner, Arnold & Porter has moved to Immediate Past Chair. Also serving on the Executive Committee are Secretary and General Counsel, Amy Norris, Clif Bar & Company, Treasurer, Frederick R. Ball, Partner, Duane Morris LLP; and Christine M. Simmon, President and CEO, FDLI.

FDLI thanks the three outgoing members of the Board of Directors: Carla Cartwright, Johnson & Johnson; Cathy Burgess, Alston & Bird LLC; and Francis Palumbo, University of Maryland School of Pharmacy. Each made invaluable contributions to FDLI and the broader food and drug law community through their Board service.

In introducing the incoming board members, Chair Jimenez stated, “We are excited for the addition of Adora, Vernessa and Zach, as their breadth of knowledge and experience will be great assets to the Board. I look forward to their contributions and leadership they will provide to FDLI.” In recognition of Past Chair Kracov, Chair Jimenez stated, “Dan’s leadership has been a steady hand during the challenging pandemic years. We are grateful for his service, and look forward to building on the strong foundation established under his stewardship.

**The Food and Drug Law Institute (FDLI)** is a nonprofit membership organization that offers education, training, publications, and professional networking opportunities in the field of food and drug law. As a neutral convener, FDLI provides a venue for stakeholders to inform public policy, law, and regulation.